Newsroom | 104155 results

Sorted by: Latest

Earnings
-

BeOne Medicines gibt die Finanzergebnisse für das dritte Quartal 2026 sowie aktuelle Informationen zur Geschäftsentwicklung bekannt

SAN CARLOS, Kalif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), ein weltweit tätiges Onkologie-Unternehmen, hat heute die Finanzergebnisse und Unternehmensnachrichten für das dritte Quartal 2026 bekannt gegeben. John V. Oyler, Mitgründer, Chairman und CEO von BeOne, sagte: „Unsere starken Ergebnisse im dritten Quartal und die angehobene Gesamtjahresprognose spiegeln das anhaltend rasante globale Wachstum und unsere Führungsposition in der Hämatologie wider. Es...
-

Riassunto: BeOne Medicines annuncia i risultati finanziari e gli aggiornamenti aziendali del terzo trimestre del 2026

SAN CARLOS, California--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), azienda globale operante nel settore oncologico, ha annunciato oggi i risultati finanziari e gli aggiornamento aziendali del terzo trimestre del 2026. Il testo originale del presente annuncio, redatto nella lingua di partenza, è la versione ufficiale che fa fede. Le traduzioni sono offerte unicamente per comodità del lettore e devono rinviare al testo in lingua originale, che è l'unico giuridi...
-

Samenvatting: BeOne Medicines maakt financiële resultaten en bedrijfsupdates voor het derde kwartaal van 2026 bekend

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), een wereldwijd oncologiebedrijf, heeft vandaag de financiële resultaten en bedrijfsupdates over het derde kwartaal van 2026 bekendgemaakt. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp bedoeld en moeten worden vergeleken met de tekst in de brontaal, die als enige rechtsgeldig is....
-

Suzano Reports 36% Increase in Third Quarter Net Revenue Following Consolidation of Arbex

SAO PAULO--(BUSINESS WIRE)--Suzano (B3: SUZB3 / NYSE: SUZ) , the world’s largest pulp producer, announces its results for the third quarter of 2026 (3Q26), which for the first time include Arbex, the joint venture between Suzano and Kimberly-Clark established in July this year. Driven primarily by the consolidation of Arbex’s contribution, Suzano reported net revenue of BRL16.5 billion, an increase of 36% on the same period last year and a new quarterly record in the company’s 102-year history....
-

Northern Trust Corporation Announces Conference Calls Reviewing Earnings in 2027

CHICAGO--(BUSINESS WIRE)--Northern Trust announced its schedule for reporting financial results and hosting conference calls to review its quarterly results in 2027....
-

Ziff Davis Reports Third Quarter 2026 Financial Results

NEW YORK--(BUSINESS WIRE)--Ziff Davis, Inc. (NASDAQ: ZD) reported unaudited financial results for the third quarter ended September 30, 2026....
-

AVAT Reports Preliminary Third Quarter 2026 Financial Results and Treasury Metrics

NEW YORK--(BUSINESS WIRE)--Avalanche Treasury Co. (Nasdaq: AVAT) ("AVAT" or the "Company"), a digital asset treasury company focused on providing investors with access to the AVAX token and exposure to the growth of the Avalanche ecosystem, today provided an update on its share repurchase program and reported preliminary, unaudited financial results for the third quarter ended September 30, 2026. Preliminary Third Quarter 2026 Financial Highlights Preliminary net income of approximately $54.6 m...
-

Goldman Sachs BDC, Inc. Reports September 30, 2026 Financial Results and Announces Fourth Quarter 2026 Base Dividend of $0.32 Per Share

NEW YORK--(BUSINESS WIRE)--Goldman Sachs BDC, Inc. (“GSBD”, the “Company”, “we”, “us”, or “our”) (NYSE: GSBD) today reported financial results for the third quarter ended September 30, 2026 and filed its Form 10-Q with the U.S. Securities and Exchange Commission. QUARTERLY HIGHLIGHTS Net investment income per share and adjusted net investment income per share were $0.32 for the quarter ended September 30, 2026, equating to an annualized net investment income yield on book value of 10.9%.1 Earni...
-

Revelation Biosciences, Inc. Announces Financial Results For the Three and Nine Months Ended September 30, 2026

SAN DIEGO--(BUSINESS WIRE)--Revelation Biosciences, Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company developing innovative solutions to treat acute and chronic disease, today reported its financial results for the three and nine months ended September 30, 2026. Corporate Highlights Released results of an independent market assessment that showed a potential $94 billion total addressable market for Gemini Announced that it has selected a full-service co...
-

CORRECTING and REPLACING Nu Skin Enterprises Reports Third Quarter Earnings

PROVO, Utah--(BUSINESS WIRE)--Please replace the release with the following corrected version, which corrects Nine Months Ended September 2026 "Impact of valuation allowance on deferred tax assets" and "Adjusted net income" in the "Reconciliation of Earnings Per Share Excluding Impact of Certain Charges to GAAP Earnings Per Share" table. The updated release reads: NU SKIN ENTERPRISES REPORTS THIRD QUARTER EARNINGS Nu Skin Enterprises Inc. (NYSE: NUS) today announced third quarter revenue within...